Menarini Silicon Biosystems has signed an agreement for the acquisition of the CELLSEARCH CTC business from American company Janssen Diagnostics LLC. At the moment of closing, the ownership of the only system already cleared by the Food and Drug Administration and CE marked for detecting Circulating Tumor Cells (CTC) in cancer patients starting from a liquid biopsy, will pass into the hands of Menarini Silicon Biosystems.
Menarini Asia-Pacific's association to its parent company, Menarini Group, allows it unfettered access to a global network of R&D infrastructure. The region also presents vast opportunities for Menarini Group to tap Asia for its R&D ambitions, facilitated by a rapidly expanding patient population, quality data, skilled talents and competitive cost structure.
Building on its reputation of being a fully integrated pharmaceutical company, Menarini Group introduced its research arm – Menarini Ricerche in 1978. This follows the introduction of Italian patent protection regulation, strongly supported by Menarini Group.
Menarini Ricerche covers the full spectrum of research and development, starting with the initial stages of research and the clinical trial phases through to industrial production.
For more information on Menarini Group's research laboratories, please visit: http://www.menarini.com/r_d/R-D-Centers